Advanced

Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial.

Le Deley, Marie-Cécile; Paulussen, Michael; Lewis, Ian; Brennan, Bernadette; Ranft, Andreas; Whelan, Jeremy; Le Teuff, Gwénaël; Michon, Jean; Ladenstein, Ruth and Marec-Bérard, Perrine, et al. (2014) In Journal of Clinical Oncology 32(23). p.2440-2448
Abstract
Relative efficacy and toxicity of cyclophosphamide compared with ifosfamide are debatable. The Euro-EWING99-R1 trial asked whether cyclophosphamide may replace ifosfamide in combination with vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosphamide [VAC] v vincristine, dactinomycin, and ifosfamide [VAI]) after an intensive induction chemotherapy containing vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in standard-risk localized disease (NCT00020566).
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Clinical Oncology
volume
32
issue
23
pages
2440 - 2448
publisher
American Society of Clinical Oncology
external identifiers
  • pmid:24982464
  • wos:000340556400011
  • scopus:84905851588
ISSN
1527-7755
DOI
10.1200/JCO.2013.54.4833
language
English
LU publication?
yes
id
496b39c9-c4b9-400d-a255-2efefd50858d (old id 4583782)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24982464?dopt=Abstract
date added to LUP
2014-08-06 21:51:31
date last changed
2017-10-22 03:24:43
@article{496b39c9-c4b9-400d-a255-2efefd50858d,
  abstract     = {Relative efficacy and toxicity of cyclophosphamide compared with ifosfamide are debatable. The Euro-EWING99-R1 trial asked whether cyclophosphamide may replace ifosfamide in combination with vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosphamide [VAC] v vincristine, dactinomycin, and ifosfamide [VAI]) after an intensive induction chemotherapy containing vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in standard-risk localized disease (NCT00020566).},
  author       = {Le Deley, Marie-Cécile and Paulussen, Michael and Lewis, Ian and Brennan, Bernadette and Ranft, Andreas and Whelan, Jeremy and Le Teuff, Gwénaël and Michon, Jean and Ladenstein, Ruth and Marec-Bérard, Perrine and van den Berg, Henk and Hjorth, Lars and Wheatley, Keith and Judson, Ian and Juergens, Heribert and Craft, Alan and Oberlin, Odile and Dirksen, Uta},
  issn         = {1527-7755},
  language     = {eng},
  number       = {23},
  pages        = {2440--2448},
  publisher    = {American Society of Clinical Oncology},
  series       = {Journal of Clinical Oncology},
  title        = {Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial.},
  url          = {http://dx.doi.org/10.1200/JCO.2013.54.4833},
  volume       = {32},
  year         = {2014},
}